The level of evidence for the use of biomarkers in the early detection of prostate cancer - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Annales de Biologie Clinique Année : 2016

The level of evidence for the use of biomarkers in the early detection of prostate cancer

Pierre-Jean Lamy
Margaret Haugh
  • Fonction : Auteur
Yvonne Fulla
  • Fonction : Auteur
Agnès Georges
  • Fonction : Auteur
Sylvain Loric
Pierre-Marie Martin
  • Fonction : Auteur
  • PersonId : 1373204
  • IdRef : 067276725
Jacques Piffret
  • Fonction : Auteur
François Thuillier
  • Fonction : Auteur

Résumé

To systematically review the evidence for the use of PSA and other biomarkers in the early detection of prostate cancer, we searched PubMed for clinical trials and studies assessing PSA and other biomarkers in the early detection of prostate cancer, published between 2000 and May 2013 that included >200 subjects. The level of evidence (LOE) for clinical utility was evaluated using the tumor marker utility grading system. A total of 84 publications, corresponding to 70 trials and studies were selected for inclusion in this review. We attributed a level of evidence (LoE) of IA to PSA for early PCa detection, but we do not recommend its use in mass screening. Emerging biomarkers were assessed in prospective case-control and cohort studies: PCA3 (n=3); kallikreins (n=3); [-2]proPSA (n=5); fusion oncogenes (n=2). These studies used biopsy results for prostate cancer to determine specificity and sensitivity, but they did not assess the effect on PCa mortality. The LoE attributed was III-C. PSA can be used for early prostate cancer detection but mass screening is not recommended. Studies on other biomarkers suggest that they could be used, individually or in combination, to improve the selection of patients with elevated PSA levels for biopsy, but RCTs assessing their impact on prostate cancer management and mortality are needed. A better use of available tests is possible for men at risk in order to maximize the risk-benefit ratio.

Domaines

Chimie
Fichier non déposé

Dates et versions

hal-03578698 , version 1 (17-02-2022)

Identifiants

Citer

Pierre-Jean Lamy, Anne-Sophie Gauchez, Laurent Salomon, Margaret Haugh, Jocelyn Ceraline, et al.. The level of evidence for the use of biomarkers in the early detection of prostate cancer. Annales de Biologie Clinique, 2016, 74 (2), pp.227-232. ⟨10.1684/abc.2016.1128⟩. ⟨hal-03578698⟩
23 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More